SEC Form 4 · accession 0000886163-18-000019
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles S Berkman
Officer — SVP, Gen. Counsel & Secretary
Period of report
Feb 15, 2018
Accepted (ET)
Feb 16, 2018 · 5:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 15, 2018 | F | 524 | $157.18 | D | 25,571 | D | |
| Common StockF2 | Feb 15, 2018 | F | 252 | $157.18 | D | 25,319 | D | |
| Common StockF3 | Feb 15, 2018 | F | 260 | $157.18 | D | 25,059 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/10/2015.
- F2Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016.
- F3Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017.